Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an experimental oral treatment for obesity and related metabolic disorders.

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their weight loss when they stop taking Wegovy.

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851. Learn more on LXRX stock here.

Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...

Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical giant Novo Nordisk A/S.

The Woodlands, Texas-based Lexicon has been studying LX9851 as a standalone therapy and in combination with GLP-1 agonists such as semaglutide, the main ingredient in Novo Nordisk’s Wegovy.

The Woodlands-based Lexicon Pharmaceuticals Inc.'s stock price surged after the deal with Novo Nordisk was announced. A Houston-area pharmaceutical company has struck a billion-dollar deal with ...

Novo Nordisk has entered into an exclusive license agreement with Lexicon Pharmaceuticals Inc. for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic ...

The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.

March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing Lexicon Pharmaceuticals' (LXRX.O), opens new tab experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Lexicon is eligible to receive upfront and near-term milestone payments of up to $75 million. In total, Lexicon will be eligible to receive $1 billion in upfront and potential development, regulatory ...